Statement on Cyberattack on the European Medicines Agency
Today, Moderna was informed by the European Medicines Agency (EMA) that in connection with a recent compromise of EMA computer systems, certain documents exchanged in the context of the pre-submission discussions related to Moderna’s COVID-19 vaccine candidate, mRNA-1273, were unlawfully accessed. Moderna’s submission to the EMA did not include any information identifying individual study participants and, thus, there is no information at this time that any study participants have been identified in any way. Moderna has not identified any indications of compromise of its own data or systems in conjunction with this incident. We await further information from EMA’s continuing investigation as Moderna continues to focus on bringing an effective and safe COVID-19 vaccine to the public.